Editas Medicine Inc (NASDAQ:EDIT) traded at $8.13 at close of the session on Friday, March 15, made a downward move of -0.25% on its previous day’s price.
Looking at the stock we see that its previous close was $8.15 and the beta (5Y monthly) reads 2.05 . In terms of its 52-week price range, EDIT has a high of $11.91 and a low of $6.08. The company’s stock has gained about 2.65% over that past 30 days.
Editas Medicine Inc has a market cap of $665.12 million and is expected to release its quarterly earnings report on May 03, 2024 – May 07, 2024. Estimates by analysts give the company expected earnings per share (EPS) of -$0.67, with the EPS growth for the year raised at -$2.66 for 2024 and -$2.74 for next year. These figures represent -31.70% and -3.00% growth in EPS for the two years respectively.
The median projection represents growth adding up to -19.80% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2024 is expected to hit $35.66 million, or -54.40% down from figures reported last year.
There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the EDIT stock, short term indicators assign the stock an average of Hold, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 50% Sell.
Looking further, we note the current price level is -8.26% off its SMA20 and -3.35% from its 50-day simple moving average. The RSI (14) is pointing at 44.37 while the volatility over the past week is 5.51% and jumps to 7.45% over the past one month. The beta value is 2.05, while the average true range (ATR) is currently pointing at 0.63.
Coming back to Editas Medicine Inc (NASDAQ:EDIT), we note that the average 3-month trading volume was 1.83 million, while that of the preceding 10-day period stands at 2.26 million. Current shares outstanding are 81.77 million.
The insiders hold 1.22% of the company’s shares while institutions hold 73.22%. The data shows that short shares as of Feb 29, 2024, stood at 13.52 million at a short ratio of 6.88. This represents a 16.52% short interest in shares outstanding on Feb 29, 2024. Shares short rose in February from the previous month at 12.21 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -19.74% down in year-to-date price movement.
